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Abstract
Background Long-term, real-world data are required to support the use of CT-P13 in chronic conditions such as ankylosing 
spondylitis. However, real-world evidence may be influenced by selection bias, which can confound outcomes. The aim of 
the current analysis was to confirm the long-term comparability of CT-P13 and reference infliximab treatment in patients 
with ankylosing spondylitis, using propensity score matching to adjust for baseline differences between groups.
Methods A propensity score–matching analysis was conducted on data from patients with ankylosing spondylitis in the 
Korean College of Rheumatology Biologics registry who received CT-P13 or reference infliximab. Drug retention, reasons 
for biologic therapy changes or discontinuation, and efficacy parameters were analyzed overall and by treatment line with 
up to 4 years of follow-up. Adverse events were recorded for each treatment group.
Results Propensity score matching was effective in matching 124 CT-P13–treated and 124 reference infliximab-treated 
patients. Median treatment duration and drug retention were similar between CT-P13 and reference infliximab. Three-year 
retention rates (95% confidence interval [CI]) were 64.2% (53.5–73.0) for CT-P13 and 55.6% (42.9–66.6) for reference 
infliximab. Overall, 17.1% (CT-P13) and 29.3% (reference infliximab) of patients discontinued biologic therapy, and 20.0% 
(CT-P13) and 15.2% (reference infliximab) changed biologic therapy. Efficacy assessments were generally similar between 
groups; both treatments were well tolerated.
Conclusions Propensity score–matching analysis confirmed that CT-P13 treatment was not associated with significant dif-
ferences in drug retention, treatment duration, most efficacy parameters, or safety versus reference infliximab in Korean 
patients with ankylosing spondylitis, building evidence for the long-term comparability of these treatments.
Trial registration ClinicalTrials.gov identifier: NCT01965132.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4025 9-020-00432 -z) contains 
supplementary material, which is available to authorized users.
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1  Background
Ankylosing spondylitis (AS) is an inflammatory rheu-
matic disease characterized by back pain and structural 
and functional systemic features that can impair quality of 
life [1]. Being a long-term disease, the cost burden of AS 
is substantial. Annual healthcare expenditures for patients 
with AS in the Republic of Korea are high, particularly in 
cases with systemic manifestations and comorbidities that 
increase disability [2]. While the advent of biologic therapy 
has improved the quality of life of patients with AS, its use 
is constrained by high costs [3]. In Korea, for example, the 
cost of illness with biologic therapies is approximately dou-
ble that of non-biologics [3], and overall expenditure has 
grown significantly year on year since the approval of the 
first biologic agents in 2006 [2]. Biosimilars have the poten-
tial to help alleviate the cost burden of biologic therapies 
and improve patient access, without compromising efficacy 
or quality of life [4, 5].
CT-P13 is a biosimilar of reference infliximab approved 
by the Korean Ministry of Food and Drug Safety [6], the 
European Medicines Agency, and the US Food and Drug 
Administration for the treatment of patients in all indica-
tions held by reference infliximab, including those with 
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Key Points 
Propensity score matching was used to adjust for base-
line differences between 124 CT-P13–treated and 124 
reference infliximab-treated patients with ankylosing 
spondylitis who were included in the Korean College of 
Rheumatology Biologics registry.
Over a follow-up period of up to 4 years, treatment 
duration and retention rate did not significantly dif-
fer between CT-P13 and reference infliximab, efficacy 
assessments were generally similar between groups, and 
both treatments were well tolerated.
These real-world, long-term findings provide robust 
evidence of the comparability of CT-P13 and reference 
infliximab, supporting the routine clinical use of CT-P13 
in patients with ankylosing spondylitis.
comparable for CT-P13 and reference infliximab in patients 
with rheumatoid arthritis [23].
While registries provide valuable, real-world data, selec-
tion bias is an inherent limitation of these non-randomized, 
observational studies, and this can confound outcome data. 
Propensity score matching (PSM) is a useful tool to adjust 
for baseline differences between treatment groups in these 
contexts [24]. The present analysis aimed to address this 
limitation of the KOBIO registry by implementing PSM, 
seeking to confirm the comparability of CT-P13 and refer-
ence infliximab in the AS patient population.
2  Methods
2.1  Study Population
The present analysis included data from patients aged ≥ 18 
years with AS who were enrolled in the KOBIO registry. 
Patients had received treatment with CT-P13 between 
December 2012 and December 2017, either as first-line 
treatment or following failure of another tumor necrosis 
factor (TNF) inhibitor. PSM was used to match the group 
of CT-P13–treated patients with an equal number of AS 
patients who received reference infliximab between Decem-
ber 2012 and December 2017. All patients were treated at 
the discretion of the treating physician, including the selec-
tion of biologic, dosing, and treatment duration. This analy-
sis was conducted according to the principles of the Declara-
tion of Helsinki, and the study protocol and data collection 
forms were approved by institutional review boards or local 
ethics committees at each participating center. All patients 
provided informed written consent.
2.2  Data Collection and Outcomes
Data were collected at baseline and annually thereafter from 
the 44 participating hospitals in the Republic of Korea, using 
standardized case report forms. The primary outcome of this 
analysis was drug retention, defined as the time to treatment 
discontinuation or change of biologic therapy. Efficacy assess-
ments were included as secondary outcomes of this analysis. 
Efficacy was assessed by Bath Ankylosing Spondylitis Dis-
ease Activity Index (BASDAI) score, Ankylosing Spondylitis 
Disease Activity Score (ASDAS)–erythrocyte sedimentation 
rate (ESR) score, ASDAS–C-reactive protein (CRP) score, 
and patient global assessment (GA). Data were also collected 
on treatment dates and line of therapy, treatment changes and 
reasons for changing, treatment discontinuations (defined as 
permanent discontinuation of biologic agents), and reasons for 
discontinuation. Patients who did not have a documented time 
to discontinuation were included in the analyses of baseline 
demographics, efficacy, and safety, but were excluded from 
AS [7–12]. A wealth of evidence from clinical trials and 
observational studies supports the comparability of CT-P13 
and reference infliximab in terms of pharmacokinetics, 
efficacy, and safety across indications [13–16]. However, 
limited data are available regarding long-term treatment 
with CT-P13. The PLANETAS study and its open-label 
extension phase demonstrated that up to 2 years of CT-P13 
treatment was well tolerated and effective [17, 18], while a 
single-center study reported a higher 2-year retention rate for 
CT-P13 compared with reference infliximab [19]. In addi-
tion, the NOR-SWITCH extension study (in which 18% of 
the patients had spondyloarthritis) reported no difference in 
safety and efficacy between patients maintaining CT-P13 
treatment for 78 weeks versus those who switched from 
reference infliximab at week 52 [20]. Additional long-term 
data are needed to confirm the utility, efficacy, and safety of 
CT-P13 therapy and its equivalence to reference infliximab 
throughout the course of this chronic inflammatory disease.
The Korean College of Rheumatology Biolog-
ics (KOBIO) registry (ClinicalTrials.gov identifier 
NCT01965132) is an ongoing, multicenter, prospective, 
observational study being conducted nationwide in the 
Republic of Korea [21]. This real-world registry was estab-
lished in December 2012 as an inception cohort to gather 
and monitor data on disease activity, treatment patterns, 
efficacy, and safety in adult patients with AS, rheumatoid 
arthritis, or psoriatic arthritis who were eligible to initiate, 
restart, or change biologic therapies. Previous analyses of 
patients from the KOBIO registry have reported encour-
aging drug retention rates, efficacy, and safety for CT-P13 
treatment in patients with AS, after 4 years of follow-up 
[22]. In addition, each of these outcomes was shown to be 
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the analysis of drug retention. Overall safety data, in terms of 
adverse events (AEs), were also collected.
2.3  Statistical Analyses
As appropriate, continuous variables for baseline character-
istics were compared using the paired t test or the Wilcoxon 
signed-rank test, and categorical variables were compared 
using McNemar’s test. PSM was used to match patients receiv-
ing CT-P13 or reference infliximab. A 1:1 ratio between the 
CT-P13 and reference infliximab group was selected to increase 
the statistical power of the analysis and to maximize the number 
of patients included in the database. Propensity scores were 
calculated using a logistic regression model to predict the prob-
ability of being treated with CT-P13 given the baseline char-
acteristics. The baseline characteristics included in the logistic 
regression model were age, sex, and baseline BASDAI score.
Drug retention was analyzed by treatment; and within 
treatment groups, drug retention was analyzed according 
to treatment line (first vs subsequent line). To account for 
the varied follow-up periods for different patients, due to 
the prospective, observational design of the KOBIO reg-
istry, we analyzed drug survival using the Hall–Wellner 
method to calculate 95% confidence intervals (CIs) for the 
Kaplan–Meier drug survival curve [25]. Treatment dura-
tion was compared between treatment groups and analyzed 
within treatment groups according to treatment line.
Efficacy was assessed as ‘major’ improvement in ASDAS 
scores [26, 27]. Major improvement was defined as improve-
ment of at least 2 points between two consecutive ASDAS 
scores. Assessment in Ankylosing Spondylitis Response 
Criteria (ASAS20) improvement was defined as an improve-
ment of at least 20% and an absolute improvement of at least 
10 units on a scale of 0–100 in at least three of the follow-
ing domains: patient GA, pain assessment, function (BAS-
DAI), and inflammation (based on the last two questions 
of the BASDAI). ASAS40 was defined as for ASAS20, but 
required improvements of at least 40% in at least three of the 
constituent domains. Descriptive statistics were derived for 
baseline and follow-up scores for BASDAI, ASDAS-ESR, 
ASDAS-CRP, and patient GA.
All statistical analyses were two-sided and were per-
formed using SAS statistical software, version 9.4 (SAS 
Institute, Cary, NC, USA), and p values < 0.05 were con-
sidered statistically significant.
3  Results
3.1  Patient Characteristics
Of the 3424 patients included in the KOBIO registry 
between December 2012 and December 2017, 1658 had 
been diagnosed with AS [22]. Among AS patients included 
in the registry, 256 received treatment with CT-P13 and 
143 received treatment with reference infliximab. Of these 
patients, 124 CT-P13–treated patients were propensity score 
matched with 124 patients who received treatment with ref-
erence infliximab; these 248 patients comprise the overall 
study population reported herein.
Following PSM, there were no significant differences 
overall in baseline patient characteristics between the 
CT-P13 group and the matched reference infliximab group 
(Table 1). Table S1 in the electronic supplementary mate-
rial shows the baseline characteristics for the 124 patients 
included in the analysis and the 132 patients who were not 
included after PSM. Ninety-eight of 124 patients (79.0%) 
in the CT-P13 group and 81 of 124 patients (65.3%) in the 
reference infliximab group were treated in the first-line set-
ting (Table S2 in the electronic supplementary material). 
There were no significant differences in baseline charac-
teristics after PSM between the CT-P13 and reference inf-
liximab groups for the 179 patients receiving first-line bio-
logic therapy, with the exception of mean disease duration, 
which was longer in the CT-P13 group (3.9 ± 5.2 vs 2.5 
± 3.8 years, respectively; p = 0.01). For patients receiving 
treatment in the subsequent-line setting (n = 69), baseline 
characteristics were generally comparable between groups 
after PSM (Table S3 in the electronic supplementary mate-
rial). However, the CT-P13 group had a significantly shorter 
mean disease duration, higher mean ASDAS-CRP score, and 
higher CRP levels compared with the reference infliximab 
group. Among patients receiving subsequent-line treatment, 
prior TNF inhibitors were most commonly etanercept (n = 
9), adalimumab (n = 8), or reference infliximab (n = 6) 
in the CT-P13 group, while stopping and restarting previ-
ous reference infliximab treatment (n = 16) was the single 
most common occurrence in the reference infliximab group 
(Table S4 in the electronic supplementary material).
3.2  Treatment Duration
After 4 years of follow-up, there was no significant differ-
ence in median treatment duration between the CT-P13 
and reference infliximab groups (Table S5 in the electronic 
supplementary material). The median (interquartile range 
[IQR]) treatment duration was 2.06 (0.99–3.05) years for 
the CT-P13 group and 1.75 (0.97–2.24) years for the refer-
ence infliximab group (p = 0.11). There were also no sig-
nificant differences in median treatment duration between 
the CT-P13 and reference infliximab groups when consider-
ing the subgroups of patients receiving first-line or subse-
quent-line treatment. However, there was a slightly longer 
median treatment duration in the CT-P13 versus the refer-
ence infliximab group in the first-line setting (2.13 [IQR 
1.02–3.07] years vs 1.64 [IQR 0.99–2.18] years; p = 0.06). 
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Corresponding median treatment durations in the subse-
quent-line subgroup were 1.11 (IQR 0.41–2.99) years and 
1.85 (IQR 0.95–2.58) years (p = 0.75).
3.3  Drug Retention
Overall, the primary outcome, drug retention, was similar 
between the CT-P13 and reference infliximab groups (p = 
0.41; Fig. 1a). Drug retention was also similar between the 
CT-P13 and reference infliximab groups in patients who 
received first-line therapy (p = 0.15; Fig. 1b) and subse-
quent-line therapy (p = 0.45; Fig. 1c). The 3-year retention 
rate (95% CI) was 64.2% (53.5–73.0) for CT-P13 and 55.6% 
(42.9–66.6) for reference infliximab in the overall patient 
population. Among patients receiving first-line therapy, the 
retention rate (95% CI) was 66.3% (54.3–75.8) for CT-P13 
and 50.6% (34.7–64.6) for reference infliximab after 3 years 
of follow-up, while corresponding retention rates (95% CI) 
in patients receiving subsequent-line therapy were 55.6% 
(30.4–74.9) and 64.6% (41.7–80.4).
The retention rates for CT-P13 and reference inflixi-
mab by treatment line are shown in Fig. S1a in the elec-
tronic supplementary material. Among patients receiving 
CT-P13, drug retention was not significantly different for 
patients receiving first-line or subsequent-line treatment (p 
= 0.30; Fig. S1b in the electronic supplementary material). 
In the reference infliximab group, drug retention was similar 
between patients receiving first- and subsequent-line treat-
ment (p = 0.40; Fig. S1c in the electronic supplementary 
material).
3.4  Treatment Changes and Discontinuations
A total of 21 patients (of 105 evaluable; 20.0%) in the 
CT-P13 cohort and 14 patients (of 92 evaluable; 15.2%) in 
the reference infliximab group changed to another biologic, 
while 18 (17.1%) and 27 patients (29.3%), respectively, dis-
continued biologic therapy (Table 2).
Changes in treatment to other biologics due to ineffi-
cacy or AEs occurred at comparable rates in both treatment 
Table 1  Baseline patient characteristics after propensity score matching
Data presented are mean (standard deviation), unless otherwise indicated
ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BMI body mass index, 
CRP C-reactive protein, ESR erythrocyte sedimentation rate, GA global assessment, HLA-B27 human leukocyte antigen-B27
Characteristics Overall (N = 248) CT-P13 (n = 124) Reference infliximab (n = 124) p value
Age at start, years 39.2 ± 13.4 38.6 ± 13.3 39.7 ± 13.5 0.50
Disease duration, years 4.3 ± 5.3 4.2 ± 5.2 4.3 ± 5.4 0.94
Male, n (%) 184 (74) 94 (76) 90 (73) 0.60
Smoking status, n (%) 0.74
 Ex-smoker 51 (21) 26 (21) 25 (20)
 Current smoker 71 (29) 33 (27) 38 (31)
 Never 126 (51) 65 (52) 61 (49)
BMI, kg/m2 23.6 ± 3.2 23.8 ± 3.2 23.3 ± 3.2 0.17
Swollen joint counts 0.6 ± 1.9 0.8 ± 2.4 0.4 ± 1.0 0.11
Tender joint counts 0.8 ± 2.4 1.1 ± 3.1 0.5 ± 1.2 0.07
BASDAI 5.5 ± 1.9 5.5 ± 1.9 5.5 ± 2.0 0.50
Patient’s GA 5.8 ± 2.2 5.8 ± 2.1 5.8 ± 2.2 0.76
ASDAS-ESR 3.5 ± 1.1 3.4 ± 1.0 3.5 ± 1.1 0.51
ASDAS-CRP 3.3 ± 1.1 3.4 ± 1.0 3.3 ± 1.2 0.21
ESR, mm/h, n (%)
 Normal 84 (34) 44 (36) 40 (33) 0.59
 ESR 35.7 ± 30.8 34.9 ± 31.9 36.4 ± 29.9 0.71
CRP, mg/dL, n (%)
 Normal 90 (37) 39 (32) 51 (41) 0.16
 CRP 2.2 ± 3.2 2.3 ± 3.2 2.1 ± 3.3 0.47
HLA-B27 status, n (%) 0.32
 Not determined 17 (7) 11 (9) 6 (5)
 Positive 206 (83) 98 (79) 108 (87)
 Negative 25 (10) 15 (12) 10 (8)
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groups. Of the 21 patients in the CT-P13 group who 
changed treatment, 13 did so due to lack of efficacy and 
eight due to AEs, while corresponding numbers of patients 
in the reference infliximab group were nine and five (14 
patients changed biologic in total). Infusion or injection site 
reactions were the most frequent AE leading to a change 
in treatment in both the CT-P13 and reference infliximab 
groups (Table 3). Skin rash accounted for three patients 
and uveitis accounted for one patient changing biologic in 
the CT-P13 group, while skin rash accounted for the one 
remaining patient changing treatment due to an AE in the 
reference infliximab group. The drugs administered follow-
ing a change in biologic treatment are presented in Table S6 
in the electronic supplementary material. Golimumab was 
the most frequently administered biologic for the CT-P13 
group, regardless of treatment line, while adalimumab was 
most frequently administered for the reference infliximab 
group, again regardless of treatment line. Two patients 
changed from CT-P13 to reference infliximab, due to AE 
(n = 1) and inefficacy (n = 1), while three patients changed 
from reference infliximab to CT-P13, due to inefficacy (n = 
2) and AE (n = 1).
Discontinuation of CT-P13 occurred due to AEs, clinical 
remission, inefficacy, and other reasons in five, four, two, 
and seven patients, respectively; corresponding numbers of 
patients discontinuing treatment in the reference infliximab 
group were 12, three, one, and 11 (Table 2). In the CT-P13 
group, AEs leading to treatment discontinuation comprised 
infusion or injection site reactions (n = 2), headache (n = 2) 
and Mycobacterium tuberculosis pulmonary infection (n = 
1) (Table 3). In the reference infliximab group, discontinua-
tions due to AEs occurred most frequently as a result of M. 
tuberculosis pulmonary infection (n = 4) and infusion or 
injection site reactions (n = 2).
3.5  Efficacy
After both 1 and 2 years of follow-up, there were no sta-
tistically significant differences between the CT-P13 and 
reference infliximab groups with regard to the proportion 
of patients who achieved major (≥ 2-point) improvement 
in ASDAS scores from baseline (Table 4). This finding was 
consistent in the subgroup of patients receiving first-line 
treatment. In terms of ASAS20 and ASAS40, there were no 
significant differences in the proportion of patients achieving 
these responses between treatment groups at either follow-
up time point.
In general, efficacy assessments were similar between the 
CT-P13 and reference infliximab groups during the follow-
up period of up to 4 years (Table S7 in the electronic sup-
plementary material). Median CRP levels were the major 
exception to this finding, as they were significantly lower in 
the reference infliximab group compared with the CT-P13 
group at 2, 3, and 4 years of follow-up. At the year 1 fol-
low-up, ASDAS-ESR and patient’s GA were significantly 
higher for the reference infliximab group compared with the 
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Fig. 1  Drug  retentiona up to 4 years in all patients (a) and those 
receiving first-line (b) and subsequent-line treatment (c) analyzed 
by Kaplan–Meier and Hall–Wellner methods to account for the var-
ied follow-up periods of different patients due to the prospective, 
observational design of the KOBIO registry. Shading indicates 95% 
Hall–Wellner bands; + indicates censored patients. KOBIO Korean 
College of Rheumatology Biologics. aDefined as time to discontinua-
tion or change of biologic therapy
534 H.-A. Kim et al.
Table 2  Reasons for changing to another biologic or discontinuation of therapy
AE adverse event
CT-P13 (N = 105) Reference infliximab (N = 92)
Overall  
(N = 105)
First line  
(n = 82)




First line  
(n = 62)
Subsequent 
line (n = 30)
Patients changing biologic or discon-
tinuing therapy, n
39 30 9 41 29 12
Patients changing biologic, n 21 15 6 14 10 4
 Inefficacy 13 10 3 9 6 3
 AE 8 5 3 5 4 1
Patients discontinuing therapy, n 18 15 3 27 19 8
 Clinical remission 4 4 3 2 1
 Inefficacy 2 2 1 1
 AE 5 4 1 12 9 3
 Other reasons 7 5 2 11 7 4
  Loss to follow-up 2 2 2 1 1
  Optionally stopped 1 1 1 1
  Patient’s will 2 1 1 5 3 2
  Plan for pregnancy 1 1 1 1
  Insurance costs 2 2
  Unknown 1 1
Table 3  Changes and discontinuations due to AEs, overall and by treatment line
AE adverse event
CT-P13 (N = 105) Reference infliximab (N = 92)
Overall  
(N = 105)
First line  
(n = 82)




First line  
(n = 62)
Subsequent 
line (n = 30)
Patients changing biologic or discontinuing therapy due to an AE, n
 Total 13 9 4 17 13 4
  Changed biologic 8 5 3 5 4 1
  Discontinued therapy 5 4 1 12 9 3
AEs leading to changed biologic or discontinued therapy, n
 Changed biologic
  Infusion/injection reaction 5 2 3 5 4 1
  Uveitis 1 1
  Skin rash 3 3 1 1
 Discontinued therapy
  Infusion/injection reaction 2 1 1 2 1 1
  Mycobacterium tuberculosis 
infection pulmonary
1 1 4 4
  Headache 2 2
  Other infection 1 1
  Transaminitis only 1 1
  Psoriasis 1 1
  Uveitis 1 1
  Gastric ulcer 1 1
  Acute kidney injury 1 1
  Unknown 1 1
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3.6  Safety
CT-P13 and reference infliximab were well tolerated dur-
ing long-term treatment. Overall, 65 patients (52.4%) 
reported 214 AEs in the CT-P13 group, while 52 patients 
(41.9%) reported 151 AEs in the reference infliximab group 
(Table S8 in the electronic supplementary material). In 
the CT-P13 group, 23 patients (18.5%) experienced a total 
of 60 AEs that were considered by the investigators to be 
study drug related; 19 patients (15.3%) in the reference 
infliximab group experienced 42 AEs that were consid-
ered by the investigators to be study drug related (Table S9 
in the electronic supplementary material). Three grade 3 
CT-P13–related AEs were reported: uveitis, infusion or 
injection site reaction, and M. tuberculosis infection, which 
occurred in one patient each. A total of three grade 3 refer-
ence infliximab-related AEs were reported, all due to M. 
tuberculosis infection.
4  Discussion
In this analysis of the real-world, prospective, observational 
KOBIO registry, our data showed no significant differ-
ences in treatment duration between CT-P13 and reference 
infliximab in patients with AS, regardless of treatment line. 
Treatment changes due to inefficacy and AEs occurred 
at comparable rates between the two study groups. Drug 
retention (time to treatment discontinuation or change) was 
not significantly different between CT-P13 and reference 
infliximab. With regard to efficacy and disease activity, in 
general, we did not observe significant differences between 
CT-P13 and reference infliximab, and both treatments were 
well tolerated. These data contribute to the evidence base for 
CT-P13 treatment, providing further support for the equiva-
lence of CT-P13 and reference infliximab in patients with 
AS over the long term.
In our analysis, the 3-year retention rate (95% CI) was 
64.2% (53.5–73.0) for CT-P13 and 55.6% (42.9–66.6) for 
reference infliximab in the overall patient population. There-
fore, the CT-P13 retention rate based on the 124 patients 
included in this analysis was similar to the 4-year retention 
rate of 66% reported in a previous analysis of 244 patients 
with AS enrolled in the KOBIO registry [22]. In addition, 
CT-P13 retention did not differ significantly between patients 
receiving first-line or subsequent-line therapy, in keeping 
with previous findings from this registry [22]. The 77% 
and 79% 1-year retention rates for CT-P13 and reference 
infliximab, respectively, in our analysis were slightly lower 
than those reported for the DANBIO registry of patients 
Table 4  Major improvement and clinically important improvements in ASDAS and improvements in ASAS at first and second follow-up: 
CT-P13 versus reference infliximab* 
Data presented are n (%)
ASAS Assessment in Ankylosing Spondylitis Response Criteria, ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylos-
ing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, GA global assessment
*Significant p value (p < 0.05)
† P value based on Chi-square test
a ASAS Response Criteria (ASAS20) is defined as an improvement of at least 20% and an absolute improvement of at least 10 units on a 0–100 
scale in at least three of the following domains: patient GA, pain assessment, function (BASFI), and inflammation (last two questions of BAS-
DAI)
b ASAS40 is defined as for ASAS20 above, but with improvements of at least 40%
Overall patient population Year 1 Year 2
CT-P13 (n = 64) Reference infliximab 
(n = 38)
P  value† CT-P13 (n = 48) Reference infliximab 
(n = 31)
p  value†
 ASAS20a 46 (71.9) 28 (73.7) 0.07 36 (75.0) 23 (74.2) 0.23
 ASAS40b 34 (53.1) 21 (55.3) 0.17 28 (58.3) 15 (48.4) 0.11
 ASDAS improvement criteria
  Major improvement 34 (34.3) 26 (31.0) 0.13 28 (43.1) 18 (34.6) 0.98
Patients receiving first-line treat-
ment
CT-P13 (n = 52) Reference infliximab 
(n = 31)
P  value† CT-P13 (n = 39) Reference infliximab 
(n = 22)
p  value†
 ASAS20a 36 (69.2) 23 (74.2) 0.51 29 (55.8) 17 (77.3) 0.51
 ASAS40b 25 (48.1) 17 (54.8) 0.80 23 (44.2) 12 (54.5) 0.35
 ASDAS improvement criteria
  Major improvement 30 (39.0) 23 (41.1) 0.13 23 (44.2) 14 (40.0) 0.72
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with rheumatic diseases, where overall crude retention rates 
(95% CI) were 84.1% (81.3–86.5) and 86.2% (84.0–88.0) 
for CT-P13 and reference infliximab, respectively [15]. In 
patients with axial spondyloarthritis alone, the correspond-
ing rate for CT-P13 was 87% (83–91) [15]. The 1- and 2-year 
retention rates in our analysis were similar to the 83% and 
76%, respectively, reported in a pooled analysis of 12 regis-
tries in the EuroSpA collaboration, including 2935 patients 
with AS [28]. On the other hand, the drug survival rates 
identified in our analysis were slightly lower than the 1-, 
2-, and 3-year retention rates reported for the 657 patients 
with AS treated with any TNF inhibitor who were included 
in the Spanish BIOBADASER registry [29] and the 310 
patients with AS treated with anti-TNF therapy who were 
included in the Czech national registry, ATTRA [30]. In 
addition, a single-center study enrolling patients with rheu-
matic diseases (including 109 patients [27.6%] with AS or 
spondyloarthritis) found that drug retention after 2 years was 
significantly better for patients who initiated CT-P13 rather 
than reference infliximab, in the combined patient popula-
tion [19], contrasting with the findings of our analysis.
In this analysis, 20.0% and 17.1% of patients receiv-
ing CT-P13 changed to another biologic and permanently 
discontinued biologic treatments, respectively. This is 
fairly similar to the rates reported in a previous analysis of 
244 patients with AS in the KOBIO registry (15.6% and 
13.1%, correspondingly) [22]. While proportions of patients 
changing to another biologic were similar between groups, 
a greater proportion of patients receiving reference inflixi-
mab discontinued biologic therapy (29.3% vs 17.1% in the 
CT-P13 group), in contrast to what might be expected with 
biosimilar-related nocebo effects [31]. This may be related to 
an increased readiness of physicians to recommend discon-
tinuation of the reference product, perceiving that reinstating 
treatment later with a first biosimilar option might provide 
similar treatment outcomes, in contrast with possible prefer-
ences of physicians already prescribing a biosimilar to main-
tain treatment with that agent. In this analysis, two patients 
switched from CT-P13 to reference infliximab, which could 
reflect patients experiencing nocebo effects with the biosimi-
lar in this observational setting [31], although three patients 
underwent the reverse switch. AEs and lack of efficacy were 
the most common reasons for patients changing biologic or 
discontinuing treatment, while clinical remission was also a 
frequent reason for treatment discontinuation. These findings 
are in keeping with the previous KOBIO registry analysis 
[22]. Similarly, AEs were the most common reason for refer-
ence infliximab discontinuation for patients with AS in the 
ATTRA registry [30] and for patients with spondyloarthritis 
in the BIOBADASER registry [29], and lack of efficacy was 
the most common reason for treatment discontinuation for 
patients with AS in the Swedish ARTIS registry who were 
treated with reference infliximab, adalimumab, or etanercept 
[32].
In the current analysis, major improvement in ASDAS 
criteria was achieved by 34.3% and 43.1% of CT-P13–treated 
patients after 1 and 2 years of treatment, respectively. This is 
somewhat lower than the corresponding 56.5% and 56.9% of 
patients reported in a previous analysis of patients with AS 
included in the KOBIO registry [22], which may be a result 
of the differences in baseline characteristics between the 
studies. Nonetheless, efficacy was similar between CT-P13 
and reference infliximab in both analyses. This is in keep-
ing with findings from the multicenter, phase I, randomized, 
double-blind PLANETAS study, which reported highly sim-
ilar efficacy across endpoints between CT-P13 and refer-
ence infliximab [13, 17], as well as comparable efficacy for 
long-term CT-P13 treatment and switching from reference 
infliximab to CT-P13 in the open-label extension [33]. Real-
world efficacy data for CT-P13 treatment in patients with AS 
have recently been reported. In an observational study that 
enrolled patients with AS with inadequate response to con-
ventional therapy, 80.0% of patients responded to CT-P13 
treatment per BASDAI criteria, which was deemed in keep-
ing with the PLANETAS study results [34]. A prospective 
observational study also compared continued reference inf-
liximab treatment with switching to CT-P13 in patients with 
AS in clinical remission [35]. After 18 months of follow-up, 
efficacy was comparable between groups and all patients 
remained in clinical remission, in keeping with the com-
parable efficacy identified between groups in our study. In 
addition, two small studies evaluating switching from refer-
ence infliximab to CT-P13 in patients with rheumatologic 
diagnoses including AS found that, overall, responses were 
similar between treatments [36, 37].
Overall, long-term treatment with both CT-P13 and refer-
ence infliximab was well tolerated. A greater number of AEs 
and a greater proportion of patients experiencing AEs were 
reported for the CT-P13 group compared with the reference 
infliximab group. However, similar proportions of patients 
in each group (CT-P13 18.5%; reference infliximab 15.3%) 
experienced AEs that were considered by the investigators to 
be study drug related. For the CT-P13 group, the proportion 
of patients reporting any or study drug-related AEs was in 
line with findings from a previous analysis of AS patients 
from the KOBIO registry [22].
The KOBIO registry prospectively collects real-world 
patient data, without protocolized patient selection or man-
dated treatment as typically employed in clinical trials, and 
thus should be more representative of everyday clinical prac-
tice. Furthermore, the implementation of PSM can provide 
more robust data than conventional observational studies, 
through avoiding any selection bias associated with differ-
ing baseline patient characteristics [24]. This means that our 
results should reflect findings for patients with AS who are 
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treated with CT-P13 or reference infliximab in the real-world 
clinical setting. However, only 69 patients (27.8%) included 
in this analysis received either CT-P13 or reference infliximab 
in the subsequent-line setting, which could have skewed the 
drug retention data in this subgroup. In addition, due to the 
prospective, observational design of the KOBIO registry, only 
eight out of 248 patients treated with CT-P13 or reference inf-
liximab were followed up for 4 years, limiting the conclusions 
that could be drawn about the retention rate at this time point; 
therefore, we have described 3-year retention rates for our anal-
ysis. Our analysis is also limited by its retrospective, observa-
tional nature, which means that some information could not be 
obtained; for example, efficacy data were not collected for all 
patients and some reasons for treatment discontinuation were 
recorded as ‘unknown.’ A further limitation to the interpreta-
tion of the efficacy data is that for some parameters, such as 
CRP, measurement methods were not standardized between 
the participating centers. A key strength of the present analysis 
is the long duration of follow-up. As previously discussed, few 
studies to date have reported on the long-term drug retention, 
efficacy, or safety of CT-P13 in patients with AS, with the 
duration of follow-up limited to up to 2 years in contexts other 
than the KOBIO registry [19, 20, 33]. The 4 years of follow-
up, to date, in the KOBIO registry provides unique insights 
into long-term treatment with CT-P13 and its comparability 
with reference infliximab. The availability of such data may 
contribute to alleviating any physician concerns regarding 
initiating, or switching patients to, a biosimilar drug such as 
potential loss of efficacy, unanticipated AEs or other safety 
considerations, or changes in immunogenicity [38]. Since bio-
logic therapies contribute significantly to the overall treatment 
cost of AS in countries, including the Republic of Korea [2], 
overcoming such concerns may substantially reduce the cost 
burden of biologic therapies in rheumatologic conditions, and 
increase patient access to these therapies [4, 39, 40].
5  Conclusions
CT-P13 treatment was not associated with significant differ-
ences in drug retention, treatment duration, or most efficacy 
parameters when compared with reference infliximab treat-
ment in Korean patients with AS. These real-world, long-term 
findings add to our increasing understanding of the compa-
rability of CT-P13 and reference infliximab, and support the 
routine clinical use of CT-P13 in patients with AS.
Acknowledgements Medical writing support (including development 
of a draft outline and subsequent drafts in consultation with the authors, 
assembling tables and figures, collating author comments, copyediting, 
fact checking, and referencing) was provided by Beatrice Tyrrell, DPhil 
at Aspire Scientific (Bollington, UK), and funded by Celltrion Health-
care Co., Ltd. (Incheon, Republic of Korea). Drafts of the manuscript 
were reviewed by Dasom Choi at Celltrion Healthcare Co., Ltd.
Authors Contributions H-AK and KS made a substantial contribution 
to the conception or design of the study, and all authors made a sub-
stantial contribution to the acquisition, analysis, and interpretation of 
the data and to manuscript development, and gave final approval of the 
manuscript for submission. KS is the guarantor for the overall content 
of the article.
Data Availability All data generated or analyzed during this study are 
included in this published article and its accompanying supplementary 
information file.
Compliance with Ethical Standards 
Conflict of interest The authors, Hyoun-Ah Kim, Eunyoung Lee, Sun-
Kyung Lee, Yong-Beom Park, and Kichul Shin, declare that they have 
no competing interests.
Funding Medical writing assistance was funded by Celltrion Health-
care Co., Ltd. (Incheon, Republic of Korea).
Research involving human participants The analysis was conducted 
in accordance with the ethical standards laid down in the 1964 Dec-
laration of Helsinki and its later amendments or comparable ethical 
standards. The study protocol and data collection forms were approved 
by institutional review boards or local ethics committees at each par-
ticipating center.
Informed consent Informed consent was obtained from all individual 
participants included in the study.
Open Access This article is licensed under a Creative Commons Attri-
bution-NonCommercial 4.0 International License, which permits any 
non-commercial use, sharing, adaptation, distribution and reproduction 
in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Com-
mons licence, and indicate if changes were made. The images or other 
third party material in this article are included in the article’s Creative 
Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons 
licence and your intended use is not permitted by statutory regula-
tion or exceeds the permitted use, you will need to obtain permission 
directly from the copyright holder. To view a copy of this licence, visit 
http://creat iveco mmons .org/licen ses/by-nc/4.0/.
References
 1. Braun J, Sieper J. Ankylosing spondylitis. Lancet. 
2007;369(9570):1379–90.
 2. Lee JS, Oh BL, Lee HY, Song YW, Lee EY. Comorbidity, disabil-
ity, and healthcare expenditure of ankylosing spondylitis in Korea: 
a population-based study. PLoS One. 2018;13(2):e0192524.
 3. Lee TJ, Park BH, Kim JW, Shin K, Lee EB, Song YW. Cost-of-
illness and quality of life in patients with ankylosing spondylitis at 
a tertiary hospital in Korea. J Korean Med Sci. 2014;29(2):190–7.
 4. Jha A, Upton A, Dunlop WC, Akehurst R. The budget impact 
of biosimilar infliximab (Remsima®) for the treatment of 
autoimmune diseases in five European countries. Adv Ther. 
2015;32(8):742–56.
 5. Kay J, Schoels MM, Dorner T, Emery P, Kvien TK, Smo-
len JS, et al. Consensus-based recommendations for the use of 
biosimilars to treat rheumatological diseases. Ann Rheum Dis. 
2018;77(2):165–74.
538 H.-A. Kim et al.
 6. Generics and Biosimilars Initiative. Biosimilar monoclonal anti-
body approved in Korea. 2012. http://www.gabio nline .net/Biosi 
milar s/News/Biosi milar -monoc lonal -antib ody-appro ved-in-Korea 
. Accessed 12 Sept 2019.
 7. European Medicines Agency. Inflectra Summary of Product 
Characteristics. 2019. https ://www.ema.europ a.eu/en/docum ents/
produ ct-infor matio n/infle ctra-epar-produ ct-infor matio n_en.pdf. 
Accessed 30 Sept 2019.
 8. European Medicines Agency. Remsima Summary of Product 
Characteristics. 2019. http://www.ema.europ a.eu/docs/en_GB/
docum ent_libra ry/EPAR_-_Produ ct_Infor matio n/human /00257 
6/WC500 15087 1.pdf. Accessed 30 September 2019.
 9. European Medicines Agency. Remicade Summary of Product 
Characteristics. 2019. https ://www.ema.europ a.eu/en/docum ents/
produ ct-infor matio n/remic ade-epar-produ ct-infor matio n_en.pdf. 
Accessed 30 Sept 2019.
 10. US Food & Drug Administration. Inflectra Prescribing Informa-
tion. 2019. https ://www.acces sdata .fda.gov/drugs atfda _docs/label 
/2019/12554 4s009 lbl.pdf. Accessed 30 Sept 2019.
 11. US Food & Drug Administration. Remicade Prescribing Informa-
tion. 2018. https ://www.acces sdata .fda.gov/drugs atfda _docs/label 
/2018/10377 2s538 5lbl.pdf. Accessed 30 Sept 2019.
 12. Korean Ministry of Food and Drug Safety. Remsima. https ://nedru 
g.mfds.go.kr/pbp/CCBBB 01/getIt emDet ail?itemS eq=20120 6204 
[in Korean]. Accessed 17 Oct 2019.
 13. Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, 
et al. A randomised, double-blind, multicentre, parallel-group, 
prospective study comparing the pharmacokinetics, safety, and 
efficacy of CT-P13 and innovator infliximab in patients with 
ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 
2013;72(10):1605–12.
 14. Jorgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, 
Haavardsholm EA, et al. Switching from originator infliximab to 
biosimilar CT-P13 compared with maintained treatment with orig-
inator infliximab (NOR-SWITCH): a 52-week, randomised, dou-
ble-blind, non-inferiority trial. Lancet. 2017;389(10086):2304–16.
 15. Glintborg B, Sorensen IJ, Loft AG, Lindegaard H, Linauskas 
A, Hendricks O, et al. A nationwide non-medical switch from 
originator infliximab to biosimilar CT-P13 in 802 patients with 
inflammatory arthritis: 1-year clinical outcomes from the DAN-
BIO registry. Ann Rheum Dis. 2017;76(8):1426–31.
 16. Baji P, Pentek M, Szanto S, Geher P, Gulacsi L, Balogh O, et al. 
Comparative efficacy and safety of biosimilar infliximab and other 
biological treatments in ankylosing spondylitis: systematic litera-
ture review and meta-analysis. Eur J Health Econ. 2014;15(Suppl 
1):S45–52.
 17. Park W, Yoo DH, Jaworski J, Brzezicki J, Gnylorybov A, Kadinov 
V, et al. Comparable long-term efficacy, as assessed by patient-
reported outcomes, safety and pharmacokinetics, of CT-P13 and 
reference infliximab in patients with ankylosing spondylitis: 
54-week results from the randomized, parallel-group PLANETAS 
study. Arthritis Res Ther. 2016;18:25.
 18. Park DJ, Choi SJ, Shin K, Kim HA, Park YB, Kang SW, et al. 
Switching profiles in a population-based cohort of rheumatoid 
arthritis receiving biologic therapy: results from the KOBIO reg-
istry. Clin Rheumatol. 2017;36(5):1013–22.
 19. Nikiphorou E, Hannonen P, Asikainen J, Borodina J, Kokko A, 
Paalanen K, et al. Survival and safety of infliximab bio-original 
and infliximab biosimilar (CT-P13) in usual rheumatology care. 
Clin Exp Rheumatol. 2018;37(1):55–9.
 20. Goll GL, Jorgensen KK, Sexton J, Olsen IC, Bolstad N, Haavard-
sholm EA, et al. Long-term efficacy and safety of biosimilar 
infliximab (CT-P13) after switching from originator infliximab: 
open-label extension of the NOR-SWITCH trial. J Intern Med. 
2019;285(6):653–69.
 21. ClinicalTrials.gov. NCT01965132: Korean College of Rheuma-
tology Biologics registry (KOBIO).https://clinicaltrials.gov/ct2/
show/NCT01965132. Accessed 30 Sept 2019.
 22. Kim HA, Lee E, Lee SK, Park YB, Lee YN, Kang HJ, et al. 
Retention rate and long-term safety of biosimilar CT-P13 in 
patients with ankylosing spondylitis: data from the Korean Col-
lege of Rheumatology Biologics registry. Clin Exp Rheumatol. 
2020;38(2):267–74.
 23. Kim H-A, Lee E-Y, Lee SK, Park Y-B, Lee YN, Kang H, et al. 
Retention rate and safety of biosimilar CT-P13 in rheumatoid 
arthritis: data from the Korean College of Rheumatology Biolog-
ics registry. BioDrugs. 2020;34(1):89–98.
 24. Okoli GN, Sanders RD, Myles P. Demystifying propensity scores. 
Br J Anaesth. 2014;112(1):13–5.
 25. Hall WJ, Wellner JA. Confidence bands for a survival curve from 
censored data. Biometrika. 1980;67:133–43.
 26. Machado P, Landewe R, Lie E, Kvien TK, Braun J, Baker D, et al. 
Ankylosing spondylitis disease activity score (ASDAS): defining 
cut-off values for disease activity states and improvement scores. 
Ann Rheum Dis. 2011;70(1):47–53.
 27. Machado PM, Landewe RB, van der Heijde DM. Endorsement of 
definitions of disease activity states and improvement scores for 
the Ankylosing Spondylitis Disease Activity Score: results from 
OMERACT 10. J Rheumatol. 2011;38(7):1502–6.
 28. Ornbjerg LM, Brahe CH, Askling J, Ciurea A, Mann H, Onen F, 
et al. Treatment response and drug retention rates in 24 195 bio-
logic-naive patients with axial spondyloarthritis initiating TNFi 
treatment: routine care data from 12 registries in the EuroSpA 
collaboration. Ann Rheum Dis. 2019;78(11):1536–44.
 29. Carmona L, Gomez-Reino JJ, Group B. Survival of TNF antago-
nists in spondylarthritis is better than in rheumatoid arthritis. Data 
from the Spanish registry BIOBADASER. Arthritis Res Ther. 
2006;8(3):R72.
 30. Pavelka K, Forejtova S, Stolfa J, Chroust K, Buresova L, Mann 
H, et al. Anti-TNF therapy of ankylosing spondylitis in clinical 
practice. Results from the Czech national registry ATTRA. Clin 
Exp Rheumatol. 2009;27(6):958–63.
 31. Kravvariti E, Kitas GD, Mitsikostas DD, Sfikakis PP. Nocebos in 
rheumatology emerging concepts and their implications for clini-
cal practice. Nat Rev Rheumatol. 2018;14(12):727–40.
 32. Lie E, Kristensen LE, Forsblad-d’Elia H, Zverkova-Sandstrom T, 
Askling J, Jacobsson LT, et al. The effect of comedication with 
conventional synthetic disease modifying antirheumatic drugs on 
TNF inhibitor drug survival in patients with ankylosing spondy-
litis and undifferentiated spondyloarthritis: results from a nation-
wide prospective study. Ann Rheum Dis. 2015;74(6):970–8.
 33. Park W, Yoo DH, Miranda P, Brzosko M, Wiland P, Gutierrez-
Urena S, et al. Efficacy and safety of switching from reference 
infliximab to CT-P13 compared with maintenance of CT-P13 
in ankylosing spondylitis: 102-week data from the PLANETAS 
extension study. Ann Rheum Dis. 2017;76(2):346–54.
 34. Codreanu C, Sirova K, Jarosova K, Batalov A. Assessment of 
effectiveness and safety of biosimilar infliximab (CT-P13) in 
a real-life setting for treatment of patients with active rheuma-
toid arthritis or ankylosing spondylitis. Curr Med Res Opin. 
2018;34(10):1763–9.
 35. Kaltsonoudis E, Pelechas E, Voulgari PV, Drosos AA. Maintained 
clinical remission in ankylosing spondylitis patients switched 
from reference infliximab to its biosimilar: an 18-month com-
parative open-label study. J Clin Med. 2019;8(7):E956.
 36. Benucci M, Gobbi FL, Bandinelli F, Damiani A, Infantino M, 
Grossi V, et al. Safety, efficacy and immunogenicity of switching 
from innovator to biosimilar infliximab in patients with spondy-
loarthritis: a 6-month real-life observational study. Immunol Res. 
2017;65(1):419–22.
539Retention Rate and Efficacy of CT-P13 and reference Infliximab in Ankylosing Spondylitis Patients
 37. Malaiya RMZ, Kiely P. Infliximab biosimilars—switching Remi-
cade to Remsima in routine care: patient acceptability and early 
outcome data. Rheumatology. 2016;55:i125–6.
 38. Azevedo V, Dörner T, Strohal R, Isaacs J, Castañeda-Hernández 
G, Gonçalves J, et al. Biosimilars: considerations for clinical prac-
tice. Consid Med. 2017;1:13–8.
 39. Gulacsi L, Brodszky V, Baji P, Kim H, Kim SY, Cho YY, et al. 
Biosimilars for the management of rheumatoid arthritis: economic 
considerations. Expert Rev Clin Immunol. 2015;11(Suppl 
1):S43–52.
 40. Brodszky V, Baji P, Balogh O, Pentek M. Budget impact analysis 
of biosimilar infliximab (CT-P13) for the treatment of rheuma-
toid arthritis in six Central and Eastern European countries. Eur 
J Health Econ. 2014;15(Suppl 1):S65–71.
Affiliations
Hyoun‑Ah Kim1  · Eunyoung Lee2,3 · Sun‑Kyung Lee4 · Yong‑Beom Park5 · Kichul Shin4 
1 Department of Rheumatology, Ajou University School 
of Medicine, Suwon, Republic of Korea
2 Department of Biomedical Informatics, Ajou University 
School of Medicine, Suwon, Republic of Korea
3 Office of Biostatistics, Ajou Research Institute for Innovative 
Medicine, Ajou University Medical Center, Suwon, 
Republic of Korea
4 Division of Rheumatology, Seoul Metropolitan 
Government-Seoul National University Hospital Boramae 
Medical Center, Seoul, Republic of Korea
5 Department of Internal Medicine (Division 
of Rheumatology), Yonsei University College of Medicine, 
Severance Hospital, Seoul, Republic of Korea
